RxDoctor Payments Data

David Jerome, DO

Family Medicine · Peekskill, NYNPI 1811309800

Payments from drug & device makers

$1,087in general payments, 2019–2025

Across 21 payments — averaging $51.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$346
  • Vivus LLC$199
  • Gilead$162
  • Boehringer Ingelheim$124
  • Janssen Products, LP$99
  • Merck$85
  • plus $73 from 2 others

What the payments were for

  • Food & beverage$98891%
  • Education$999%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,087 in reported general payments places this provider in the 65th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$11,928
Medicare patients
76
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$80,313
JardianceEmpagliflozin77$69,608
JanuviaSitagliptin Phosphate50$38,254
EliquisApixaban48$35,468
DescovyEmtricitabine/Tenofov Alafenam14$35,110
TrulicityDulaglutide13$22,721
FarxigaDapagliflozin Propanediol31$18,277
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$17,228
RybelsusSemaglutide15$17,055
JanumetSitagliptin Phos/Metformin Hcl11$13,077
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$8,827
EntrestoSacubitril/Valsartan12$7,381
Tresiba Flextouch U-100Insulin Degludec14$6,566
SymbicortBudesonide/Formoterol Fumarate29$6,325
TradjentaLinagliptin13$6,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$124$75,92690 claims
MerckJanuvia, Janumet$85$51,33161 claims
GileadDescovy$162$35,11014 claims
GSKTrelegy Ellipta, Incruse Ellipta$346$23,11634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,321 family medicine providers in New York.

Other family medicine in Peekskill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →